<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>489</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15501759</PubmedId>
            <Abstract>Protective antigen (PA) is central to the action of the lethal and edema toxins produced by Bacillus anthracis. It is the common cell-binding component, mediating the translocation of the enzymatic moieties (lethal factor [LF] and edema factor) into the cytoplasm of the host cell. Monoclonal antibodies (MAbs) against PA, able to neutralize the activities of the toxins in vitro and in vivo, were screened. Two such MAbs, named 7.5 and 48.3, were purified and further characterized. MAb 7.5 binds to domain 4 of PA and prevents the binding of PA to its cell receptor. MAb 48.3 binds to domain 2 and blocks the cleavage of PA into PA63, a step necessary for the subsequent interaction with the enzymatic moieties. The epitope recognized by this antibody is in a region involved in the oligomerization of PA63; thus, MAb 48.3 does not recognize the oligomer form. MAbs 7.5 and 48.3 neutralize the activities of anthrax toxins produced by B. anthracis in mice. Also, there is an additive effect between the two MAbs against PA and a MAb against LF, in protecting mice against a lethal challenge by the Sterne strain. This work contributes to the functional analysis of PA and offers immunotherapeutic perspectives for the treatment of anthrax disease.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>6313-7</ArticlePages>
            <ArticleTitle>Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Brossier</LastName>
                    <ForeName>Fabien</ForeName>
                </Author>
                <Author>
                    <LastName>Lévy</LastName>
                    <ForeName>Martine</ForeName>
                </Author>
                <Author>
                    <LastName>Landier</LastName>
                    <ForeName>Annie</ForeName>
                </Author>
                <Author>
                    <LastName>Lafaye</LastName>
                    <ForeName>Pierre</ForeName>
                </Author>
                <Author>
                    <LastName>Mock</LastName>
                    <ForeName>Michèle</ForeName>
                </Author>
            </Authors>
            <Affiliations>Unité Toxines et Pathogénie Bactériennes, URA 2172, CNRS, Institut Pasteur, 28 rue du Dr. Roux, 75724 Paris Cedex 15, France.</Affiliations>
            <ArticleChemicalList>Antibodies, Bacterial;Antibodies, Monoclonal;Antigens, Bacterial;Bacterial Toxins;anthrax toxin</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Animals, Outbred Strains; Anthrax(immunology; microbiology; prevention &amp; control); Antibodies, Bacterial(immunology; therapeutic use); Antibodies, Monoclonal(immunology; therapeutic use); Antigens, Bacterial(immunology; toxicity); Bacillus anthracis(immunology; pathogenicity; physiology); Bacterial Toxins(immunology; toxicity); CHO Cells; Cell Line; Cricetinae; Epitope Mapping; Humans; Macrophages; Mice; Neutralization Tests; Spores, Bacterial(pathogenicity)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>72</Volume>
                <Issue>11</Issue>
                <Title>Infection and immunity</Title>
                <Issn>0019-9567</Issn>
                <MedlineTa>Infect Immun</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>412-419</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SKNLAPI</LinearSequence>
                        <StartingPosition>442</StartingPosition>
                        <EndingPosition>448</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P13423.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1392</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Text</LocationOfData>
                <EpitopeId>58906</EpitopeId>
                <ReferenceStartingPosition>412</ReferenceStartingPosition>
                <ReferenceEndingPosition>419</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>1384791</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000026</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Protective antigen precursor</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Mice were immunized s.c. with 20 micrograms PA83 in CFA.  Four s.c. boosters in IFA were given 1, 3, 5, and 7 weeks later. Fifteen days later mice received final i.p. booster of antigen.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>To produce hybridoma, splenocytes were harvested and fused to mouse myeloma cells (x63Ag8-653).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The antibody, previously shown to bind to the epitope, was able to neutralyze Ltheal toxin effects on macrophages. This in not mediated through an inbition of PA binding but of the Fruin cleavage and heptamerization of PA63.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 48.3</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Bacillus anthracis</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1325074</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000026</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Protective antigen precursor</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Mice were immunized s.c. with 20 micrograms PA83 in CFA.  Four s.c. boosters in IFA were given 1, 3, 5, and 7 weeks later. Fifteen days later mice received final i.p. booster of antigen.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>To produce hybridoma, splenocytes were harvested and fused to mouse myeloma cells (x63Ag8-653).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>125</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The antibody, previously shown to bind to the epitope, was able to protect mice from challenge with anthrax.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 48.3</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Bacillus anthracis</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Text</LocationOfData>
                        <BCellId>7391</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000026</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Protective antigen precursor</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Mice were immunized s.c. with 20 micrograms PA83 in CFA.  Four s.c. boosters in IFA were given 1, 3, 5, and 7 weeks later. Fifteen days later mice received final i.p. booster of antigen.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>To produce hybridoma, splenocytes were harvested and fused to mouse myeloma cells (x63Ag8-653).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Sequencing of phage-display library (Ph.D. 7) clones selected by binding to the Pa83 source protein resulted in 2 consensus groups, yielding a homologous sequence within PA83 corresponding to 412 SKNLAPI 419.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 48.3</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Protective antigen precursor</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P13423.2</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Domain 4 amino acids 608-735</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVINDRYDMLNISSLRQDGKTFIDFKKYNDKLPLYISNPNYKVNVYAVTKENTIINPSENGDTSTNGIKKILIFSKKGYEIG</LinearSequence>
                        <StartingPosition>637</StartingPosition>
                        <EndingPosition>764</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P13423.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1392</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Text</LocationOfData>
                <EpitopeId>8176</EpitopeId>
                <ReferenceStartingPosition>608</ReferenceStartingPosition>
                <ReferenceEndingPosition>735</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Text</LocationOfData>
                        <BCellId>1325078</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000026</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Protective antigen precursor</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Mice were immunized s.c. with 20 micrograms PA83 in CFA.  Four s.c. boosters in IFA were given 1, 3, 5, and 7 weeks later. Fifteen days later mice received final i.p. booster of antigen.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>To produce hybridoma, splenocytes were harvested and fused to mouse myeloma cells (x63Ag8-653).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope was mapped using Western blots with both native and mutant protective antigen.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 7.5</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Protective antigen precursor</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P13423.2</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1325079</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000026</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Protective antigen precursor</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Mice were immunized s.c. with 20 micrograms PA83 in CFA.  Four s.c. boosters in IFA were given 1, 3, 5, and 7 weeks later. Fifteen days later mice received final i.p. booster of antigen.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>To produce hybridoma, splenocytes were harvested and fused to mouse myeloma cells (x63Ag8-653).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>125</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The antibody, previously shown to bind to the epitope, was able to protect mice from challenge with anthrax.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 7.5</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Bacillus anthracis</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

